Scientific Publications Scientific Publications Search PublicationsSubmit Additional publications and presentations Cancer Research Communications PLK1 inhibition induces synthetic lethality in Fanconi anemia pathway-deficient acute myeloid leukemia Publication | March 2025 SABCS 2024 Onvansertib Enhances the Anti-tumor Efficacy of Trastuzumab Deruxtecan in Endocrine Therapy- and CDK4/6 Inhibitor-resistant HR+/HER2- Breast Cancer Patient-derived Xenograft Models Presentation | December 2024 SABCS 2024 Onvansertib Shows Synergistic Efficacy in Combination with Paclitaxel in HR+ Breast Cancer: Mechanistic Insights from Preclinical Models Presentation | December 2024 Molecular Cancer Therapeutics AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer Publication | October 2024 Featured publications Journal of Clinical Oncology Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial Publication | October 2024 Cancers PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights Publication | September 2024 Cell Death & Disease Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas Publication | July 2024 AACR 2024 The PLK1 Inhibitor, Onvansertib, Synergizes with Paclitaxel in Small Cell Lung Cancer Presentation | April 2024 AACR 2024 In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum- resistant ovarian carcinoma patient-derived xenograft models Presentation | April 2024 AACR 2024 The PLK1 Inhibitor Onvansertib is Active as Monotherapy and in Combination with Cetuximab in RAS Wild-type Colorectal Cancer Patient-derived Xenografts Presentation | April 2024 AACR 2024 A Phase 1b/2 Clinical Study of Onvansertib in Combination with FOLFIRI/Bevacizumab Revealed a New Role of PLK1 in regulating the Hypoxia Pathway in KRAS-mutant Colorectal Cancer Presentation | April 2024 Clinical Cancer Research Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study Publication | April 2024 AACR 2024 A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with Standard-of-Care (SoC) Versus SoC Alone for First-line Treatment of RAS-mutated Metastatic Colorectal Cancer Presentation | April 2024 SABCS 2023 Combination of the PLK1 Inhibitor Onvansertib and PI3Kα Inhibitor Alpelisib is effective in Palbociclib-Resistant PIK3CA-mutated HR+ Breast Cancer Presentation | December 2023 SABCS 2023 PLK1 Inhibitor Onvansertib Extends the Response and Overcomes Resistance to Paclitaxel in Palbociclib-resistant HR+ Breast Cancer Patient-derived Xenografts Presentation | December 2023 Annals of Hematology Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia Publication | September 2023 Cancer Research Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling Publication | January 2023 ESMO 2022 Early Decreases in KRAS Mutant Allele Frequency (MAF) Predict Clinical Benefit to the PLK1 Inhibitor Presentation | September 2022 ESMO 2022 The PLK Inhibitor Onvansertib Overcomes irinotecan Resistance in the RAS-Mutated Metastatic Colorectal Cancer (mCRC) in Vivo and in Patients Presentation | September 2022 Therapeutic Advances in Medical Oncology Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas Publication | May 2022 AACR 2022 Biomarkers of Response to Abiraterone and the Polo-Like Kinase 1 (PLK1) Inhibitor Onvansertib in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Presentation | April 2022 AACR 2022 Combining PARP inhibition with the Polo-like kinase (PLK1) inhibitoronvansertib overcomes PARP inhibitor resistance Presentation | April 2022 ASCO GU 2022 A Phase 2 Study of Onvansertib in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation | February 2022 ASCO GI 2022 A Phase 1b/2 Trial of the PLK1 Inhibitor Onvansertib in Combination with FOLFIRI-bev in 2L Treatment of KRAS-Mutated Metastatic Colorectal Carcinoma (mCRC) Presentation | January 2022 AACR 2021 Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer Presentation | April 2021 AACR 2021 The Selective Polo-like Kinase (Plk1) Inhibitor Onvansertib and the Antiandrogen Abiraterone Synergistically Kill Cancer Cells Through Disruption of Mitosis Independently of Androgen Receptor Signaling Presentation | April 2021 ASCO GU 2021 A Phase 2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation | February 2021 ASCO GI 2021 Phase 1b/2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of KRAS-Mutated Metastatic Colorectal Cancer Presentation | January 2021 Clinical Cancer Research A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia Publication | December 2020 ASH 2020 Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia Presentation | December 2020 PCF Retreat 2020 A Phase 2 Study of the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Abiraterone in Patients with Abiraterone-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) Presentation | October 2020 ESMO 2020 Phase 1b/2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of KRAS-Mutated Metastatic Colorectal Cancer Presentation | September 2020 EHA 2020 Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia Presentation | June 2020 ASCO 2020 A Phase 1b/2 Study of the Polo-like Kinase 1 (PLK1) inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Presentation | May 2020 Load More
